Monday, 21 March 2016

Epilepsy Therapeutics Market Shares, Strategies And Forecasts To 2019

In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion.  Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019. 

Epilepsy is described by recurring seizures as it is a set of long-term neurological disorders.  When a group of neurons in brains or nerve cells send wrong signals, episodes of these seizures occur. Depending on the cause of the epilepsy, seizures may possibly be different from primary comprehensive seizures to partial seizures. Patients suffering from epilepsy act weirdly and grumble about strange sensations and emotions. People of all ages are being affected by epilepsy as it is the fourth most common disorder. Doctors prescribe drugs or antiepileptic medicines for the treatment of epilepsy. It depends on the age of the patient seriousness of the seizures and type of seizures to be treated 

View More Details of "Epilepsy Therapeutics Industry" @ http://www.radiantinsights.com/research/epilepsy-therapeutics-in-major-developed-markets-to-2019-new-aeds-with-novel-mechanisms-of-action-signal-a-shift-in-treatment-patterns

Recent approvals of drugs coupled with novel technologies of action are some of the factors attributing to the industry growth of the market. The U.S region contributes to the major market share for over 55% for the total market. In addition, three new anti-epileptic drugs have been permitted in the aforementioned region since 2012.  Fycompa, Trobalt and Aptiom are also projected to be launched over the coming years. Moreover, brivaracetam is likely to approve over the coming years.  Factors such as improved safety and tolerability of fycoma and trobalt are also contributing significantly owing to the increased interest of prescribers over the past few years.

Constant uptake of anti-epileptic drugs of second and third generation is anticipated to attribute towards the revenues in these regions.  Although, the market could experience the hindering impact of geriatric competition as a result of novel patent expiries in all the key industries especially for key branded drugs like Lamictal and Keppra.

Request Free Sample Of This Study @ http://www.radiantinsights.com/research/epilepsy-therapeutics-in-major-developed-markets-to-2019-new-aeds-with-novel-mechanisms-of-action-signal-a-shift-in-treatment-patterns#tabs-4

Key market players operating for epilepsy therapeutics in the major developed markets are Novartis AG, GlaxoSmithKine plc, Shire, Johnson & Johnson Pfizer,  Sanofi S.A, Cephalon, Abbot Laboratories, Sunovion Pharmaceuticals, Shire and Valeant Pharamceutical International Inc.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com 
Website: Radiant Insights

No comments: